Elsevier

Annals of Epidemiology

Volume 7, Issue 7, October 1997, Pages 486-489
Annals of Epidemiology

Original report
Blood pressure and heart rate: No evidence for a positive association with prostate cancer

https://doi.org/10.1016/S1047-2797(97)00083-5Get rights and content

Abstract

PURPOSE: This study aimed to determine whether blood pressure and heart rate are correlated with the development of prostate cancer.

METHODS: A total of 58,704 men whose blood pressure, heart rate, and other characteristics were measured at multiphasic checkups were followed for ⩽ 30 years. The incidence of, and mortality from, prostate cancer were measured. There were 2297 cases and 464 deaths.

RESULTS: No evidence of a positive association of blood pressure or heart rate with subsequent prostate cancer was found.

CONCLUSIONS: Data from this large population lend no support for concerns that higher levels of blood pressure or heart rate are linked to increased risk of prostate cancer.

References (25)

  • AR Dyer et al.

    High blood-pressure: A risk factor for cancer mortality?

    Lancet

    (1975)
  • M Pahor et al.

    Calcium-channel blockade and incidence of cancer in aged populations

    Lancet

    (1996)
  • RA Hiatt et al.

    The frequency of kidney and urinary tract diseases in a defined population

    Kidney Int

    (1982)
  • PH Gann et al.

    Heart rate and prostate cancer mortality: results of a prospective analysis

    Cancer Epidemiol Biomarkers Prev

    (1995)
  • J Wang et al.

    Requirement of innervation for maintenance of structural and functional integrity in the rat prostate

    Biol Reprod

    (1991)
  • KT McVary et al.

    Growth of the rat prostate gland is facilitated by the autonomic nervous system

    Biol Reprod

    (1994)
  • S Furukawa et al.

    Nerve growth factor synthesis and its regulatory mechanisms: an approach to therapeutic induction of nerve growth factor synthesis

    Cerebrovas Brain Metab Rev

    (1990)
  • SC Jacobs et al.

    Exocrine secretion of epidermal growth factor by the rat prostate: effect of adrenergic agents, cholinergic agents, and vasoactive intestinal peptide

    Prostate

    (1988)
  • K Svärdsudd et al.

    Mortality and morbidity during 13.5 years' follow-up in relation to blood pressure

    Acta Med Scand

    (1979)
  • WJ Raynor et al.

    High blood pressure and 17-year cancer mortality in the Western Electric Health study

    Am J Epidemiol

    (1981)
  • G Wannamethee et al.

    Blood pressure and cancer in middle-aged British men

    Int J Epidemiol

    (1996)
  • G Wannamethee et al.

    Heart rate, physical activity, and mortality from cancer and other noncardiovascular diseases

    Am J Epidemiol

    (1993)
  • Cited by (24)

    • A role for cAMP-driven transactivation of EGFR in cancer aggressiveness - Therapeutic implications

      2014, Medical Hypotheses
      Citation Excerpt :

      Obesity/metabolic syndrome, tobacco use, and lack of exercise can all raise the pulse rate [119–121] while also increasing cancer risk and mortality [122–124]; the fact that heart rate persists as a determinant of cancer mortality after statistical adjustment for these factors is consistent with the thesis that sympathetic drive per se increases risk for cancer death, and may in fact mediate, in part, the increased cancer risk associated with metabolic syndrome, smoking, and sedentary lifestyle. Prospective analyses examining prostate cancer specifically have concluded that heart rate correlates positively with prostate cancer incidence [125] and mortality [126], albeit one study could not confirm such a relationship [127]. Inasmuch as most of these studies deal with cancer mortality – as opposed to incidence – they do not clarify to what extent an impact on cancer prognosis may have played a role in the higher cancer mortality observed with high pulse rate.

    • Constitutional risk factors in prostate cancer

      2011, Actas Urologicas Espanolas
    View all citing articles on Scopus

    This work was supported by grant no. R35 CA94761 from the National Cancer Institute.

    View full text